BIRMINGHAM, Ala. - People with chronic kidney disease have a higher risk for heart disease and heart-disease death. Now, for the first time in humans, research led by Navkaranbir Bajaj, M.D., of the University of Alabama at Birmingham, has identified a pathological change that appears to link kidney disease to progressive heart disease.
This offers a potential treatment target, which could have wide benefit because 14 percent of the U.S. adult population has chronic kidney disease. The research is published in the journal Circulation, with Bajaj -- a UAB assistant professor in the Division of Cardiovascular Disease, Department of Medicine and Department of Radiology -- as first author.
"I am now collaborating with other UAB researchers to figure out how we can target therapeutics to help these patients," Bajaj said.
The pathological change identified is coronary microvascular dysfunction, or CMD, say Bajaj and research colleagues at Harvard Medical School. CMD is decreased blood flow in the small blood vessels inside the heart muscle that provide oxygen and fuel to feed the pumping heart.
In healthy hearts, visualized postmortem, these blood vessels look like a tight filigree network that fills the heart muscle tissue. A diseased postmortem heart has lost much of this network. In living patients, however, those small blood vessels inside the heart muscle cannot be visualized; blood flow scans of living patients visualize only the larger, exterior coronary arteries. So Bajaj and colleagues needed an indirect way to gauge CMD.
That measure is coronary flow reserve, or CFR, which Bajaj and colleagues measured via positron emission tomography. CFR is the maximum increase in blood flow through the coronary arteries above the normal resting volume. Bajaj, a cardiologist who trained at UAB, did his advanced imaging fellowship at Brigham and Women's Hospital in Boston, before returning to UAB in 2018.
In a longitudinal study of 352 patients with chronic kidney disease, all with healthy heart function as measured by ejection fraction and none with signs of overt coronary artery disease, the researchers measured CFR and also measured signs of subclinical heart dysfunction via deformation analysis with echocardiograms. The patients were then followed a median of 4.4 years for major adverse cardiac events. A total of 108 patients had such major events, including death and hospitalization for non-fatal heart attack or heart failure.
The researchers found that CMD was a significant predictor of abnormal mechanics of the left ventricle -- the heart's major pumping chamber -- and a significant predictor of clinical risk of adverse cardiovascular outcomes.
A statistical model called mediation analysis examined the relationship between impaired kidney function and heart disease. It showed that CMD accounted for 19 to 24 percent of left ventricle diastolic dysfunction, 19 to 42 percent of left ventricle systolic dysfunction and 32 percent of major adverse cardiovascular events.
These significant associations "provide important new evidence that the development of severe microvascular dysfunction likely signals the transition from physiological to pathological left ventricle remodeling that increases the risk of heart failure and death in patients with chronic kidney disease," the study said. "To the best of our knowledge, our study is the first and largest to comprehensively explore these associations and to suggest a possible pathway to the development of uremic cardiomyopathy in individuals without overt ischemic heart disease."
Corresponding author of the study, "Coronary microvascular dysfunction, left ventricular remodeling, and clinical outcomes in patients with chronic kidney impairment," is Marcelo F. Di Carli, Brigham and Women's Hospital and Harvard Medical School.
Co-authors with Bajaj and Di Carli are Amitoj Singh, Wunan Zhou, Ankur Gupta, Kana Fujikura, Christina Byrne, Hendrik J. Harms, Paco Bravo, Efstathia Andrikopolou, Sanjay Divakaran, Courtney F. Bibbo, Jon Hainer, Hicham Skali, Viviany Taqueti, Michael Steigner, Sharmila Dorbala, Ron Blankstein, Rahul C. Deo and Scott D. Solomon, Brigham and Women's Hospital and Harvard Medical School; Michael T. Osborne, Massachusetts General Hospital and Harvard Medical School; David M. Charytan, New York University School of Medicine; and Sumanth D. Prabhu, Division of Cardiovascular Disease, UAB Department of Medicine.
Support for Bajaj came from an American College of Cardiology Presidential Career Development Award; National Institutes of Health grant HL094301; the Walter B. Frommeyer, Jr., Fellowship in Investigative Medicine, supported by the UAB Department of Medicine; and NIH National Center for Advancing Translational Research award TR001417.
At UAB, Sumanth D. Prabhu holds the Mary Gertrude Waters Chair of Cardiovascular Medicine.